Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 21 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.88 Insider Own28.90% Shs Outstand22.52M Perf Week-1.79%
Market Cap253.52M Forward P/E- EPS next Y-2.53 Insider Trans35.81% Shs Float21.95M Perf Month-13.67%
Income-64.12M PEG- EPS next Q-0.59 Inst Own63.20% Short Float4.94% Perf Quarter116.05%
Sales0.00M P/S- EPS this Y9.72% Inst Trans- Short Ratio1.40 Perf Half Y111.05%
Book/sh4.77 P/B1.72 EPS next Y-2.19% ROA-44.11% Short Interest1.08M Perf Year-35.96%
Cash/sh3.56 P/C2.31 EPS next 5Y- ROE-47.77% 52W Range3.19 - 14.03 Perf YTD66.87%
Dividend Est.- P/FCF- EPS past 5Y- ROI-57.52% 52W High-41.48% Beta1.10
Dividend TTM- Quick Ratio12.40 Sales past 5Y0.00% Gross Margin- 52W Low157.37% ATR (14)0.86
Dividend Ex-Date- Current Ratio12.40 EPS Y/Y TTM-66.59% Oper. Margin0.00% RSI (14)47.56 Volatility5.53% 10.89%
Employees58 Debt/Eq0.04 Sales Y/Y TTM- Profit Margin- Recom1.20 Target Price21.44
Option/ShortNo / Yes LT Debt/Eq0.03 EPS Q/Q-25.42% Payout- Rel Volume0.06 Prev Close8.55
Sales Surprise- EPS Surprise13.07% Sales Q/Q- EarningsMay 14 BMO Avg Volume776.25K Price8.21
SMA20-6.40% SMA503.70% SMA20019.62% Trades Volume44,437 Change-3.98%
Date Action Analyst Rating Change Price Target Change
Apr-29-24Downgrade Ladenburg Thalmann Buy → Neutral
Mar-01-24Initiated JMP Securities Mkt Outperform $14
Dec-15-23Resumed Jefferies Buy $17 → $12
Oct-05-23Initiated Maxim Group Buy
Jun-02-23Initiated Oppenheimer Outperform $25
May-08-23Initiated BMO Capital Markets Outperform $25
Apr-27-23Initiated Ladenburg Thalmann Buy $22
Apr-20-23Initiated H.C. Wainwright Buy $24
Dec-12-22Initiated Piper Sandler Overweight $25
Dec-12-22Initiated Jefferies Buy $17
May-20-24 09:40AM
May-14-24 01:54PM
May-10-24 08:50AM
Apr-29-24 07:08AM
04:01PM Loading…
Apr-24-24 04:01PM
Apr-16-24 08:01PM
Apr-10-24 08:00AM
Apr-09-24 10:32AM
Mar-30-24 05:31AM
Mar-28-24 12:52PM
Mar-05-24 04:30PM
Mar-04-24 08:00AM
08:00AM Loading…
Feb-27-24 08:00AM
Feb-08-24 08:00AM
Feb-06-24 08:00AM
Jan-12-24 04:00PM
Jan-04-24 08:00AM
Jan-03-24 08:00AM
Nov-28-23 08:00AM
Nov-21-23 08:00AM
Nov-09-23 08:01AM
Oct-16-23 08:00AM
Sep-28-23 04:05PM
Sep-19-23 04:32PM
Sep-05-23 04:05PM
Aug-30-23 08:00AM
04:00PM Loading…
Aug-17-23 04:00PM
Aug-11-23 07:00AM
Aug-08-23 12:38PM
Jul-20-23 08:00AM
Jun-29-23 04:49PM
Jun-22-23 04:00PM
Jun-02-23 08:00AM
May-09-23 10:43AM
May-07-23 08:17AM
Apr-25-23 08:00AM
Apr-24-23 08:00AM
Apr-18-23 08:00AM
Mar-28-23 08:00AM
Mar-06-23 08:00AM
Feb-27-23 08:00AM
Feb-15-23 05:40AM
Feb-14-23 10:15AM
Jan-22-23 03:31PM
Nov-14-22 10:16PM
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Devroe EricChief Operating OfficerMay 17 '24Option Exercise1.0410,00010,40069,097May 21 04:04 PM
PERCEPTIVE ADVISORS LLC10% OwnerApr 11 '24Buy8.502,353,00020,000,5005,360,858Apr 15 08:53 AM
Chione Ltd10% OwnerJun 26 '23Sale12.93162073,848,632Jun 28 03:47 PM
Holm-Jorgensen RasmusChief Financial OfficerJun 16 '23Option Exercise3.639,50034,48529,530Jun 20 05:21 PM
Chione Ltd10% OwnerJun 15 '23Sale12.142,05624,9603,848,648Jun 20 05:15 PM
Chione Ltd10% OwnerJun 14 '23Sale12.1389310,8323,850,704Jun 14 06:33 PM
Chione Ltd10% OwnerJun 13 '23Sale12.303,00036,9003,851,597Jun 14 06:33 PM
Chione Ltd10% OwnerJun 12 '23Sale12.342,00024,6803,854,597Jun 14 06:33 PM
Devroe EricChief Operating OfficerJun 05 '23Option Exercise1.049,2259,59462,883Jun 06 04:15 PM
Blume-Jensen PeterPresident and CEOMay 31 '23Option Exercise3.8833,605130,3872,403,702Jun 01 08:40 PM